CROI 2015 Program and Abstracts

Poster Listings

Session P-E2 Poster Session

Poster Hall

335 Enhanced Immune ReconstitutionWith Initiation of ART at HIV-1 Seroconversion (PHI) Sabine I. Kinloch 1 ; Colette Smith 1 ; KwongTsz-Shan 2 ; Jayne Ellis 2 ; Margaret Johnson 2 1 University College London, London, United Kingdom; 2 Royal Free London NHS Foundation Trust, London, United Kingdom 336 cART-Driven Recovery of Immune Function Preferentially Targeting CXCR4-Tropic HIV-1 Joëlle Bader 1 ; Martin Däumer 2 ; Jürg Böni 4 ; Meri Gorgievski 3 ;Thomas Klimkait 1 The Swiss HIV Cohort Study 1 University of Basel, Basel, Switzerland; 2 Institute for Immunogenetics, Kaiserslautern, Germany; 3 University of Berne, Berne, Switzerland; 4 Swiss National Center for Retroviruses, Zürich, Switzerland 337 Repeated injections of r-hIL-7 in HIV Patients receiving ART in INSPIRE 2 & 3 trials Rodolphe Thiebaut 1 ; Ana Jarne 1 ; Jean-Pierre Routy 2 ; Irini Sereti 3 ; Margaret A. Fischl 4 ; Prudence Ive 5 ; Roberto Speck 6 ; GiuseppeTambussi 7 ;Yves Lévy 8 ; Michael M Lederman 9 on behalf of Inspire 2 and Inspire 3 study groups 1 Bordeaux University, Bordeaux, France; 2 McGill University, Montreal, Canada; 3 National Institute of Allergy and Infectious Diseases (NIAID), Bethesda, MD, US; 4 University of Miami, Miami, FL, US; 5 Wits Health consortium, Johannesburg, South Africa; 6 University Hospital Zurich, Zurich, Switzerland; 7 San Raffaele Scientific Institute, Milano, Italy; 8 INSERM, Paris, France; 9 Case Western Reserve University, Cleveland, OH, US 338 CRF19_cpx Is an Evolutionary Fit HIV-1 Variant Exclusively Associated With Rapid Progression to AIDS in Cuba Vivian Kouri 2 ; Ricardo Khouri 1 ;Yoan Alemán 2 ;Yeissel Abrahantes 2 ; Nico Pfeifer 3 ; Andrea- Clemencia Pineda-Peña 4 ; Jorge Pérez 2 ; Lissette Pérez 2 ; KristelVan Laethem 4 ; Anne-Mieke Vandamme 4 1 Fundação Oswaldo Cruz, Salvador, Brazil; 2 Instituto Pedro Kouri, Havana, Cuba; 3 Max Planck Institute for Informatics, Saarbrucken, Germany; 4 Katholieke Universiteit Leuven, Leuven, Belgium 2:30 pm– 4:00 pm The Effect of HIV Infection on B Cells 339 Acute HIV-1 Infection Is AssociatedWith Rapid Changes in B-Cell Subsets and Levels of CXCL13 Jenniffer K. Maroa 1 ; Anne-Sophie Dugust 2 ; Zelda Euler 2 ;Yathisha Ramlakhan 1 ; Krista Dong 3 ; BruceWalker 2 ;Thumbi Ndung’u 4 ; Galit Alter 2 1 University of KwaZulu-Natal, Durban, South Africa; 2 Ragon Institute of MIT, MGH and Harvard, Boston, MA, US; 3 Massachusetts General Hospital, Harvard Medical School, Boston, MA, US; 4 HIV Pathogenesis Programme, Durban, South Africa 340 Bone Marrow Plasma Cells Dictate SerumHIV-Specific Antibodies in Chronic Viremia Jairo Mauricio Montezuma-Rusca 1 ; Olivia R. Fankuchen 1 ; Lela Kardava 1 ; Clarisa M. Buckner 1 ; Aaron Louie 1 ;Yuxing Li 2 ;TaeWook Chun 1 ; Katherine R. Calvo 3 ; Susan Moir 1 ; Anthony S. Fauci 1 1 NIAID/NIH, Bethesda, MD, US; 2 University of Maryland, Rockville, MD, US; 3 NIH Clinical Center, Bethesda, MD, US 341 Reduced Expression of Blimp-1 on Memory B Cells in Patients with HIV-1 Infection Claudia Beisel ; IlonaToth; Jan van Lunzen; Julian Schulze zurWiesch University Hospital Hamburg-Eppendorf, Hamburg, Germany 342 Similar or Higher Memory Responses to Influenza Vaccination in Aviremic HIV-infected Patients on Antiretroviral Therapy TUESDAY, FEBRUARY 24, 2015 Session P-E1 Poster Session

2:30 pm– 4:00 pm The Envelope/Antibody Dynamic 343 Estimating and Visualizing HIV-1 Susceptibility to Broadly Neutralizing Antibodies Anna Feldmann ; Nico Pfeifer Max Planck Institute for Informatics, Saarbrücken, Germany 344 Sequential SHIV-Env Clones With Neutralization Sensitivity for Breadth Development Manxue Jia ; Cecilia Cheng-Mayer; XuelingWu Aaron Diamond AIDS Research Center, New York, NY, US 345 V1V2 Neutralizing Epitopes Are ConservedWithin Divergent Groups of HIV-1 Marion Morgand 1 ; Mélanie Bouvin-Pley 1 ; Craig S Pace 2 ; David Ho 2 ; Pascal Poignard 3 ; Marie Pancera 4 ; Jean-Christophe Plantier 5 ; Francois Simon 6 ; Martine Braibant 1 ; Francis Barin 7 1 Université de Tours, Inserm U966, Tours, France; 2 Aaron Diamond AIDS Research Center, The Rockefeller University, New York, NY, US; 3 Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, CA, US; 4 Vaccine Research Center, NIAID, NIH, Bethesda, WA, US; 5 Université de Rouen, CHU Charles Nicolle, Rouen, France; 6 Laboratoire de Virologie, Hôpital St Louis, Paris, France; 7 Université de Tours, Inserm U966, Laboratoire de Bactériologie- Virologie, CNR du VIH, CHU Bretonneau, Tours, France 346 Improving Neutralization Potency and Breadth by Combining Broadly Reactive HIV-1 Antibodies Targeting Major Neutralization Epitopes Rui Kong 1 ; Mark Louder 1 ; KshitijWagh 2 ; Robert Bailer 1 ; Kelli Greene 3 ; Hongmei Gao 3 ; Michel Nussenzweig 4 ; Bette Korber 2 ; David Montefiori 3 ; John Mascola 1 1 Vaccine Research Center, NIAID, NIH, Bethesda, MD, US; 2 Los Alamos National Laboratory, Los Alamos, NM, US; 3 Duke University Medical Center, Durham, NC, US; 4 The Rockefeller University, New York, NY, US 347 Improved Antibody Cross-Neutralizing Activity in HIV-1 Dual-Infected LTNP Patients Maria Pernas 1 ; Concepción Casado 1 ;Victor Sanchez-Merino 2 ; Alberto Sanchez-Merino 2 ; Isabel Olivares 1 ; eloisaYuste 2 ; Cecilio Lopez-Galíndez 1 1 Instituto de Salud Carlos III, Majadahonda, Spain; 2 Institut d’Investigacions Biomediquès, Barcelona, Spain 348 Characterization of CD4 Independent HIV-1 Envelope as Potential Immunogens Lifei Yang 1 ; Bradley Cleveland 1 ; Andrea P. Jordan 2 ; Patricia Polacino 1 ; James A. Hoxie 2 ; Shiu-Lok Hu 1 1 University of Washington, Seattle, WA, US; 2 University of Pennsylvania, Philadelphia, PA, US 349 Phenotypic Neutralization Sieve Analysis of an SIV Nonhuman Primate Vaccine Challenge Study Fang-Hua Lee 1 ; Brandon F. Keele 3 ; Robert Doms 1 ; George M. Shaw 1 ; Mario Roederer 2 ; Katharine J. Bar 1 1 University of Pennsylvania, Philadelphia, PA, US; 2 Vaccine Research Center, NIAID, NIH, Bethesda, MD, US; 3 National Cancer Institute, Frederick, MD, US 350 AvFc, a Novel Fc Fusion Protein Targeting Env High-Mannose Glycans Nobuyuki Matoba ; Adam Husk; J. Calvin Kouokam; Krystal Hamorsky;Tiffany Grooms- Williams; Garima Mahajan University of Louisville James Graham Brown Cancer Center, Owensboro, KY, US 351 DARPins as Entry Inhibitor Alternative to HIV-1 Broadly Neutralizing Antibodies Emanuel Stiegeler ; Nikolas Friedrich;Thomas Reinberg; Mylène Morin;YufanWu; JonasV. Schaefer; Peter Rusert; John Robinson; Andreas Plückthun; AlexandraTrkola University of Zurich, Zurich, Switzerland

Poster Listings

Poster Hall

Zhenwu Luo; Lisa Martin; J. Michael Kilby; Wei Jiang Medical University of South Carolina, Charleston, SC, US

33

CROI 2015